University of SaskatchewanHARVEST
  • Login
  • Submit Your Work
  • About
    • About HARVEST
    • Guidelines
    • Browse
      • All of HARVEST
      • Communities & Collections
      • By Issue Date
      • Authors
      • Titles
      • Subjects
      • This Collection
      • By Issue Date
      • Authors
      • Titles
      • Subjects
    • My Account
      • Login
      JavaScript is disabled for your browser. Some features of this site may not work without it.
      View Item 
      • HARVEST
      • Electronic Theses and Dissertations
      • Graduate Theses and Dissertations
      • View Item
      • HARVEST
      • Electronic Theses and Dissertations
      • Graduate Theses and Dissertations
      • View Item

      Intranasal treatment with a novel immunomodulator mediates innate immune protection against lethal Pneumonia Virus of Mice.

      Thumbnail
      View/Open
      MARTINEZPENA-THESIS-2016.pdf (26.03Mb)
      Date
      2016-06-08
      Author
      Martinez Pena, Elisa Catalina 1991-
      ORCID
      0000-0003-1141-3567
      Type
      Thesis
      Degree Level
      Masters
      Metadata
      Show full item record
      Abstract
      Respiratory syncytial virus (RSV) is the major causative agent of acute lower respiratory tract infections in infants and young children. Unfortunately, there are no licensed RSV vaccines available, and the few treatment options for high-risk individuals are either extremely costly or cause severe side effects and toxicity. Thus, the development of effective vaccines and therapeutic interventions against RSV is a preeminent public health priority. Pneumonia virus of mice (PVM) causes similar clinical symptoms and disease in mice to those observed in RSV-infected patients, and therefore is used as a model for pathogenesis studies. Lethal PVM infection (i.e. 3000 pfu) in Balb/c mice is characterized by 20% weight loss in total body weight, rough coats, abnormal posture, nasal discharge, and difficulty breathing due to neutrophilia, edema and alveolitis in the lower airways. Also, these mice will succumb to the infection between days 6 and 7 p.i. Immunomodulation mediated by a novel formulation composed of the toll-like receptor 3 agonist poly I:C, an innate defense regulator peptide and a polyphosphazene (i.e. P-I-P) was first assessed in healthy adult Balb/c mice. Subsequently, the protective potential of P-I-P was further investigated in the context of a lethal PVM infection. P-I-P induced highest mRNA and protein expression of chemokines and cytokines in the lung milieu between 6 and 24 hr post-treatment. In addition, a single dose of P-I-P protected adult mice against PVM when given 24 hr prior to challenge. These animals displayed minimal body weight changes, no clinical disease, 100% survival, as well as reduced lung virus titers and pathology. P-I-P pre-treatment induced early mRNA and protein expression of key chemokine and cytokines, and decreased neutrophil and eosinophil numbers in the lungs, resulting in an overall modulation of the delayed exacerbated nature of PVM disease without short-term side effects. It was determined that the protective effects of P-I-P prophylaxis were maintained if administered up to 3 days prior to lethal PVM infection. On day 14 post-infection, P-I-P-treated survivor mice were confirmed to be PVM-free. These results demonstrate the capacity of this formulation to prevent PVM and possibly other viral respiratory infections.
      Degree
      Master of Science (M.Sc.)
      Department
      Microbiology and Immunology
      Program
      Microbiology and Immunology
      Supervisor
      van Drunen Littel-van den Hurk, Sylvia
      Committee
      Xiao, Wei; Havele, Calliope; Bull, Harold; Gordon, John R
      Copyright Date
      May 2016
      URI
      http://hdl.handle.net/10388/7278
      Subject
      PVM
      RSV
      immunomodulators
      innate immunity
      protection.
      Collections
      • Graduate Theses and Dissertations
      University of Saskatchewan

      University Library

      © University of Saskatchewan
      Contact Us | Disclaimer | Privacy